Inovio Q2 net loss $32.2M; INO-3107 BLA submission delayed to mid-2025 due to device manufacturing issue

INOVIO PHARMACEUTICALS, INC.

2024-Q2 EPS reported -$2.48 revenue$100,762

Net loss of $32.2M ($1.19/share) vs $35.5M ($1.61/share) in Q2 2023; revenue not disclosed.
Cash, equivalents and short-term investments $110.4M; cash runway estimated into Q3 2025.
BLA submission for lead candidate INO-3107 (RRP) delayed to mid-2025 due to manufacturing issue with disposable device component.
Appointed Steve Egge as Chief Commercial Officer; submitted Phase 3 trial design for INO-3112 to European regulators.
Raised $33.2M net in April 2024 stock/warrant offering.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.